20.97

5.75% 1.14

After Hours: 20.97

Mbx Biosciences Inc (MBX)

Overview News Price History Discussions Forecast

Mbx Biosciences Inc stock is traded at $20.97, with a volume of 119.08K. It is up +5.75% in the last 24 hours and down -1.27% over the past month. MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

Previous Close:

$19.83

Open:

$20.13

24h Volume:

119.08K

Relative Volume:

1.21

Market Cap:

$662.67M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+29.13%

1M Performance:

-1.27%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$20.00

$22.60

1-Week Range:

$15.65

$22.60

52-Week Range:

$15.31

$27.50

Mbx Biosciences Inc Stock (MBX) Company Profile

Name

Mbx Biosciences Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(317) 989-3100

Address

12406 HORESHAM STREET, CARMEL

Employee

Twitter

Next Earnings Date

Latest SEC Filings

MBX's Discussions on Twitter

Compare MBX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBX Mbx Biosciences Inc	20.97	662.67M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-08-24	Initiated	Guggenheim	Buy
Oct-08-24	Initiated	JP Morgan	Overweight
Oct-08-24	Initiated	Jefferies	Buy
Oct-08-24	Initiated	Stifel	Buy

Mbx Biosciences Inc Stock (MBX) Latest News

Nov 23, 2024

MBX Biosciences (NYSE:MBX) Trading Up 6.5%Still a Buy? - MarketBeat

Nov 23, 2024

Nov 19, 2024

MBX Biosciences (NYSE:MBX) Shares Gap DownHere's What Happened - MarketBeat

Nov 19, 2024

Nov 18, 2024

MBX Biosciences completes phase 1 trial of diabetes drug By Investing.com - Investing.com Canada

Nov 18, 2024

Mbx Biosciences, Inc. Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia - Marketscreener.com

Nov 18, 2024

Nov 17, 2024

MBX Biosciences (NYSE:MBX) Reaches New 12-Month Low – Here’s Why - Defense World

Nov 17, 2024

Nov 15, 2024

MBX Biosciences (NYSE:MBX) Sets New 1-Year LowTime to Sell? - MarketBeat

Nov 15, 2024

Nov 14, 2024

MBX Biosciences: Decent Potential For Lead Indication, But Need More Data (NASDAQ:MBX) - Seeking Alpha

Nov 14, 2024

Nov 13, 2024

Behind the Bell: MBX Biosciences - Nasdaq

Nov 13, 2024

Nov 09, 2024

MBX Biosciences Reports Q3 2024 Financial Progress - MSN

Nov 09, 2024

Nov 08, 2024

Wellington Management Group LLP Acquires New Stake in MBX Biosci - GuruFocus.com

Nov 08, 2024

Nov 07, 2024